Company intelligence / Profile preview

Enzyme by Design

Chicago, Illinois, United Statesenzymebydesign.com ↗

Ownership: Private
Employees: ~5
Development stage: Preclinical

Overview

Enzyme by Design’s lead program, EbD-1117, is a humanized L-asparaginase engineered to eliminate glutaminase activity—reducing the toxic side effects seen in current asparaginases. In mouse models of T-cell and B-cell ALL, EbD-1117 demonstrated efficacy comparable to standard therapies but with significantly less weight loss and reduced liver toxicity. The company aims to enter clinical trials after completing IND-enabling studies.

Therapeutic areas: Oncology
Modalities: Recombinant proteinEnzyme therapyBiologic
Industry: Biotech

Drug pipeline

1 asset

novel human-like asparaginase

Preclinical

Partnerships

None publicly disclosed as of June 2025. Participates in NIH I-CORP program for industry engagement.

Beyond the preview

Go deeper on Enzyme by Design.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Enzyme by Design.

Explore the full profile